An upcoming study at Children’s Hospital of Philadelphia will be the first of its kind in the United States to examine the benefits of medical marijuana in children with autism spectrum disorder (ASD). The study is in partnership with an Australian biopharmaceutical company called Zelda Therapeutics, who will be funding the study.
Athena Zupp, the director of Children’s Hospital’s Center for Clinical Pharmacology, told philly.com that “the hospital will not provide any cannabis products to children. This is truly an observational study. We’re not giving them anything. We’re just gathering data to educate ourselves.” The researchers will be working with children who are already covered under Pennsylvania’s Safe Harbor Provision. (Wood, 2017) The study is expected to begin early this year.